RPID Stock Analysis: Buy, Sell, or Hold?
RPID - Rapid Micro Biosystems, Inc. Class A Common Stock
$2.27
0.11 (5.09%)
▲
5d:
-0.44%
30d:
-47.94%
90d:
-21.72%
BUY
MODERATE Confidence
Analysis Updated: Apr 2, 2026 12:00 AM ET
Earnings: May 08, 2026
Get Alerted When RPID Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: RPID shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: RPID shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: RPID is currently trading at $2.27, which is considered oversold relative to its 30-day fair value range of $2.39 to $4.20.
Technical Outlook: Technically, RPID is in a downtrend. Immediate support is located at $2.01, while resistance sits at $2.58. The stock is showing strong short-term momentum, up 5.1% recently.
Market Sentiment: RPID has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $8.00 (+252.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, RPID is in a downtrend. Immediate support is located at $2.01, while resistance sits at $2.58. The stock is showing strong short-term momentum, up 5.1% recently.
Market Sentiment: RPID has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $8.00 (+252.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$2.39 -
$4.20
Company Quality Score
43/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
63.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+5.1%)
- BULLISH: Trading 252.4% below Wall St target ($8.00)
Fair Price Analysis
30-Day Fair Range
$2.39 -
$4.20
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$2.01
Resistance Level
$2.58
Current Trend
Downtrend
Technical data as of
Apr 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.87
Wall Street Target
$8.00
(+252.4%)
Revenue Growth (YoY)
37.3%
Profit Margin
-140.3%
Share & Embed Analysis
Last updated: April 02, 2026 6:56 PM ET
Data refreshes hourly during market hours. Next update: 7:56 PM
Data refreshes hourly during market hours. Next update: 7:56 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is RPID showing a specific setup today?
Insider Activity (6 Months)
0
Buys
13
Sells
Net
INSIDERS SELLING
Recent Transactions
Sean M Wirtjes
SELL
7480 shares
2026-03-11
John J Addington Wilson
SELL
9603 shares
2026-03-11
Robert G Jr. Spignesi
SELL
17922 shares
2026-03-10
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$102 | 60 HOLD |
|
ABT
Abbott Laboratories |
BUY
28 analysts |
$133 | 59 HOLD |
|
DXCM
DexCom Inc |
STRONG BUY
26 analysts |
$86 | 47 HOLD |
|
MDT
Medtronic PLC |
BUY
32 analysts |
$111 | 62 BUY |
|
PODD
Insulet Corporation |
STRONG BUY
23 analysts |
$354 | 52 HOLD |
